Drug Safety

Soleno Therapeutics Sued in Federal Securities Class Action Over DCCR Safety Disclosures

Investors have until May 5, 2026 to seek lead-plaintiff status in a case alleging misstatements about the Prader–Willi syndrome drug’s risks.